Fenwick represented SyntheX on the deal.SyntheX, a biotechnology company innovating next-generation functional drug discovery engines, announced its research collaboration and license agreement with Bristol Myers Squibb…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
